Table 1.
Characteristics of Women Undergoing RRSO in GOG-0199: National Ovarian Cancer Prevention and Early Detection Study (N = 966)*
| Characteristic | Negative RRSO (n = 941) |
Invasive Cancer/STIC (n = 25) |
P | ||
|---|---|---|---|---|---|
| No. | % | No. | % | ||
| Baseline CA-125/TVU | < .001 | ||||
| Normal/normal | 805 | 88.6 | 13 | 54.0 | |
| Abnormal/normal | 19 | 2.1 | 7 | 29.2 | |
| Normal/abnormal | 76 | 8.4 | 1 | 4.2 | |
| Abnormal/abnormal | 9 | 1.0 | 3 | 12.5 | |
| Age, years | < .001 | ||||
| Median | 47.1 | 52.7 | |||
| IQR | 41.5-53.4 | 47.9-58.3 | |||
| Menopausal status | .003 | ||||
| Premenopausal | 559 | 59.4 | 7 | 28.0 | |
| Postmenopausal | 382 | 40.6 | 18 | 72.0 | |
| Race | NS | ||||
| White | 892 | 95.3 | 24 | 96.0 | |
| Black | 32 | 3.4 | 1 | 4.0 | |
| Other | 12 | 1.3 | 0 | 0.0 | |
| Nulliparous | NS | ||||
| No | 700 | 85.0 | 15 | 71.4 | |
| Yes | 124 | 15.0 | 6 | 28.6 | |
| Family history | |||||
| Breast cancer | NS | ||||
| No | 153 | 16.8 | 1 | 4.4 | |
| Yes | 755 | 83.2 | 22 | 95.6 | |
| Ovarian cancer | NS | ||||
| No | 444 | 49.0 | 13 | 56.5 | |
| Yes | 463 | 51.0 | 10 | 43.5 | |
| BRCA mutation status† | < .001 | ||||
| Noncarrier | 401 | 42.3 | 2 | 8.0 | |
| BRCA1 positive | 311 | 33.3 | 15 | 60.0 | |
| BRCA2 positive | 223 | 23.8 | 8 | 32.0 | |
| Double positive | 2 | 0.2 | 0 | 0.0 | |
| OC use | NS | ||||
| Current | 51 | 5.4 | 0 | 0.0 | |
| Former | 630 | 67.2 | 15 | 60.0 | |
| Never | 257 | 27.4 | 10 | 40.0 | |
| Menopausal hormone use | NS | ||||
| Current | 165 | 18.2 | 1 | 4.4 | |
| Former | 269 | 29.7 | 11 | 47.8 | |
| Never | 471 | 52.0 | 11 | 47.8 | |
| Personal history of breast cancer | NS | ||||
| No | 421 | 44.7 | 10 | 40.0 | |
| Yes | 520 | 55.3 | 15 | 60.0 | |
| Tamoxifen use | .04 | ||||
| Current | 119 | 13.2 | 0 | 0.0 | |
| Former | 120 | 13.3 | 6 | 26.1 | |
| Never | 666 | 73.6 | 17 | 73.9 | |
Abbreviations: CA-125, cancer antigen 125; GOG, Gynecologic Oncology Group; IQR, interquartile range; NS, not significant; OC, oral contraceptive; RRSO, risk-reducing salpingo-oophorectomy; STIC, serous tubal intraepithelial carcinoma; TVU, transvaginal ultrasound.
*
Numbers might not add up to total of 966 because of missing values.
†
Two participants with both BRCA1 and BRCA2 mutations were excluded from this analysis.